Related Experiment Video
Updated: Jul 9, 2025

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
Published on: August 5, 2022
Methylation of the epigenetic JMJD2D protein by SET7/9 promotes prostate tumorigenesis
Ruicai Gu1, Tae-Dong Kim1, Hanlin Jiang2
1Department of Cell Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.
Abstract:
How the function of the JMJD2D epigenetic regulator is regulated or whether it plays a role in prostate cancer has remained elusive. We found that JMJD2D was overexpressed in prostate tumors, stimulated prostate cancer cell growth and became methylated by SET7/9 on K427. Mutation of this lysine residue in JMJD2D reduced the ability of DU145 prostate cancer cells to grow, invade and form tumors and elicited extensive transcriptomic changes. This included downregulation of CBLC, a ubiquitin ligase gene with hitherto unknown functions in prostate cancer, and upregulation of PLAGL1, a transcription factor with reported tumor suppressive characteristics in the prostate. Bioinformatic analyses indicated that CBLC expression was elevated in prostate tumors. Further, downregulation of CBLC largely phenocopied the effects of the K427 mutation on DU145 cells. In sum, these data have unveiled a novel mode of regulation of JMJD2D through lysine methylation, illustrated how this can affect oncogenic properties by influencing expression of the CBLC gene, and established a pro-tumorigenic role for CBLC in the prostate. A corollary is that JMJD2D and CBLC inhibitors could have therapeutic benefits in the treatment of prostate and possibly other cancers.
Insights
JMJD2D epigenetic regulator overexpression fuels prostate cancer growth. Lysine methylation of JMJD2D impacts cancer cell behavior and influences CBLC gene expression, highlighting potential therapeutic targets for prostate cancer treatment.
Area of Science:
- Epigenetics
- Molecular Oncology
- Biochemistry
Background:
- The role of the JMJD2D epigenetic regulator in prostate cancer remains unclear.
- Understanding JMJD2D regulation is crucial for identifying new therapeutic strategies.
Purpose of the Study:
- To investigate the regulation and function of JMJD2D in prostate cancer.
- To elucidate the downstream effects of JMJD2D activity on cancer progression.
Main Methods:
- Analysis of JMJD2D expression in prostate tumors.
- Site-directed mutagenesis of JMJD2D at K427.
- Cell growth, invasion, and tumor formation assays.
- Transcriptomic analysis.
- Bioinformatic analyses of gene expression.
Main Results:
- JMJD2D is overexpressed in prostate tumors and promotes cancer cell growth.
- Lysine methylation of JMJD2D at K427 by SET7/9 regulates its oncogenic function.
- K427 mutation in JMJD2D impairs DU145 cell growth, invasion, and tumor formation.
- JMJD2D activity influences the expression of CBLC (a ubiquitin ligase) and PLAGL1 (a transcription factor).
- CBLC is upregulated in prostate tumors and its downregulation mimics the effects of the K427 mutation.
Conclusions:
- A novel regulatory mechanism for JMJD2D via lysine methylation has been identified.
- JMJD2D's pro-tumorigenic role in prostate cancer is mediated partly through regulation of CBLC expression.
- CBLC exhibits a pro-tumorigenic role in prostate cancer, suggesting it as a potential therapeutic target.
- JMJD2D and CBLC inhibitors may offer therapeutic benefits for prostate cancer treatment.
Related Concept Videos
Epigenetic Regulation
X-chromosome...
Abnormal Proliferation
MicroRNAs
Induced Pluripotent Stem Cells
Somatic...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Genomic Imprinting and Inheritance
The expression of some genes depends on which parent passed the gene to the offspring, through a phenomenon known as...

